Barclays analyst Brandon Oglenski lowered the firm’s price target on RXO Inc. (RXO) to $15 from $17 and keeps an Overweight rating on the shares post the Q3 report. The company’s Q4 outlook is materially below expectations and sets up for a fourth year in 2026 of trough level earnings forecasts, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO: